114 related articles for article (PubMed ID: 26526637)
1. Blood-based Biomarkers at Large Bowel Endoscopy and Prediction of Future Malignancies.
Kring TS; Piper TB; Jørgensen LN; Olsen J; Rahr HB; Nielsen KT; Laurberg S; Davis G; Dowell B; Johansen JS; Christensen IJ; Brünner N; Nielsen HJ
Biomark Cancer; 2015; 7():57-61. PubMed ID: 26526637
[TBL] [Abstract][Full Text] [Related]
2. Serological cancer-associated protein biomarker levels at bowel endoscopy: Increased risk of subsequent primary malignancy.
Piper TB; Nielsen HJ; Christensen IJ
Tumour Biol; 2022; 44(1):1-16. PubMed ID: 35180141
[TBL] [Abstract][Full Text] [Related]
3. Increased serological cancer-associated biomarker levels at large bowel endoscopy and risk of subsequent primary cancer (†).
Hvolris MH; Piper TB; Hammer E; Jørgensen LN; Olsen J; Rahr HB; Nielsen KT; Laurberg S; Christensen IJ; Brünner N; Johansen JS; Davis GJ; Dowell BL; Nielsen HJ
Scand J Gastroenterol; 2016 Jul; 51(7):860-5. PubMed ID: 26918701
[TBL] [Abstract][Full Text] [Related]
4. Increased serological, cancer-associated protein biomarker levels at diagnosis of large bowel adenoma: Risk of subsequent primary malignancy?
Piper TB; Jørgensen LN; Olsen J; Nielsen KT; Davis G; Johansen JS; Jarle Christensen I; Nielsen HJ
Acta Oncol; 2019; 58(sup1):S42-S48. PubMed ID: 30523734
[TBL] [Abstract][Full Text] [Related]
5. Plasma TIMP-1 and CEA as Markers for Detection of Primary Colorectal Cancer: A Prospective Validation Study Including Symptomatic and Non-symptomatic Individuals.
Christensen IJ; Brünner N; Dowell B; Davis G; Nielsen HJ; Newstead G; King D
Anticancer Res; 2015 Sep; 35(9):4935-41. PubMed ID: 26254391
[TBL] [Abstract][Full Text] [Related]
6. Serum YKL-40 in risk assessment for colorectal cancer: a prospective study of 4,496 subjects at risk of colorectal cancer.
Johansen JS; Christensen IJ; Jørgensen LN; Olsen J; Rahr HB; Nielsen KT; Laurberg S; Brünner N; Nielsen HJ
Cancer Epidemiol Biomarkers Prev; 2015 Mar; 24(3):621-6. PubMed ID: 25597749
[TBL] [Abstract][Full Text] [Related]
7. Plasma TIMP-1 and CEA in detection of primary colorectal cancer: a prospective, population based study of 4509 high-risk individuals.
Nielsen HJ; Brünner N; Jorgensen LN; Olsen J; Rahr HB; Thygesen K; Hoyer U; Laurberg S; Stieber P; Blankenstein MA; Davis G; Dowell BL; Christensen IJ; ;
Scand J Gastroenterol; 2011 Jan; 46(1):60-9. PubMed ID: 20799911
[TBL] [Abstract][Full Text] [Related]
8. Clean Colorectum at Diagnostic Colonoscopy: Subsequent Detection of Extracolonic Malignancies by Plasma Protein Biomarkers?
Wilhelmsen M; Christensen IJ; Jørgensen LN; Madsen MR; Vilandt J; Hillig T; Klærke M; Nielsen KT; Laurberg S; Gawel S; Yang X; Davis G; Heijboer AM; Martens F; Nielsen HJ
Biomark Cancer; 2018; 10():1179299X18776974. PubMed ID: 29872358
[TBL] [Abstract][Full Text] [Related]
9. Predicting malignant transformation of esophageal squamous cell lesions by combined biomarkers in an endoscopic screening program.
Zhang H; Li H; Ma Q; Yang FY; Diao TY
World J Gastroenterol; 2016 Oct; 22(39):8770-8778. PubMed ID: 27818592
[TBL] [Abstract][Full Text] [Related]
10. TIMP-1 and CEA as biomarkers in third-line treatment with irinotecan and cetuximab for metastatic colorectal cancer.
Spindler KL; Christensen IJ; Nielsen HJ; Jakobsen A; Brünner N
Tumour Biol; 2015 Jun; 36(6):4301-8. PubMed ID: 25608838
[TBL] [Abstract][Full Text] [Related]
11. Detection of colorectal neoplasia: Combination of eight blood-based, cancer-associated protein biomarkers.
Wilhelmsen M; Christensen IJ; Rasmussen L; Jørgensen LN; Madsen MR; Vilandt J; Hillig T; Klaerke M; Nielsen KT; Laurberg S; Brünner N; Gawel S; Yang X; Davis G; Heijboer A; Martens F; Nielsen HJ
Int J Cancer; 2017 Mar; 140(6):1436-1446. PubMed ID: 27935033
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of combined testing of YKL-40 with CEA in Chinese colorectal cancer patients.
Ye HM; Lu YZ; Liang XM; Lin YZ; Li Y; Zhang ZY; Tzeng CM
Clin Lab; 2014; 60(3):397-405. PubMed ID: 24697115
[TBL] [Abstract][Full Text] [Related]
13. Combination of preoperative CEA and CA19-9 improves prediction outcomes in patients with resectable pancreatic adenocarcinoma: results from a large follow-up cohort.
Zhou G; Liu X; Wang X; Jin D; Chen Y; Li G; Li C; Fu D; Xu W; Wang X
Onco Targets Ther; 2017; 10():1199-1206. PubMed ID: 28280354
[TBL] [Abstract][Full Text] [Related]
14. Can preoperative CEA and CA19-9 serum concentrations suggest metastatic disease in colorectal cancer patients?
Stojkovic Lalosevic M; Stankovic S; Stojkovic M; Markovic V; Dimitrijevic I; Lalosevic J; Petrovic J; Brankovic M; Pavlovic Markovic A; Krivokapic Z
Hell J Nucl Med; 2017; 20(1):41-45. PubMed ID: 28315907
[TBL] [Abstract][Full Text] [Related]
15. The diagnostic value of serum carcino-embryonic antigen, alpha fetoprotein and carbohydrate antigen 19-9 for colorectal cancer.
Wang YR; Yan JX; Wang LN
J Cancer Res Ther; 2014 Dec; 10 Suppl():307-9. PubMed ID: 25693941
[TBL] [Abstract][Full Text] [Related]
16. Faecal calprotectin: a marker of inflammation throughout the intestinal tract.
Summerton CB; Longlands MG; Wiener K; Shreeve DR
Eur J Gastroenterol Hepatol; 2002 Aug; 14(8):841-5. PubMed ID: 12172403
[TBL] [Abstract][Full Text] [Related]
17. Tumor markers in serum and ascites in the diagnosis of benign and malignant ascites.
Zhu FL; Ling AS; Wei Q; Ma J; Lu G
Asian Pac J Cancer Prev; 2015; 16(2):719-22. PubMed ID: 25684514
[TBL] [Abstract][Full Text] [Related]
18. Are serum and biliary carcinoembryonic antigen and carbohydrate antigen19-9 determinations reliable for differentiation between benign and malignant biliary disease?
Akdoğan M; Parlak E; Kayhan B; Balk M; Saydam G; Sahin B
Turk J Gastroenterol; 2003 Sep; 14(3):181-4. PubMed ID: 14655062
[TBL] [Abstract][Full Text] [Related]
19. The Assessment of Clinical Usage and Prognostic Value of YKL-40 Serum Levels in Patients With Rectal Cancer Without Distant Metastasis.
Fuksiewicz M; Kotowicz B; Rutkowski A; Achinger-Kawecka J; Wagrodzki M; Kowalska MM
Technol Cancer Res Treat; 2018 Jan; 17():1533033818765209. PubMed ID: 29642772
[TBL] [Abstract][Full Text] [Related]
20. Plasma microRNA Levels Combined with CEA and CA19-9 in the Follow-Up of Colorectal Cancer Patients.
Pesta M; Kucera R; Topolcan O; Karlikova M; Houfkova K; Polivka J; Macanova T; Machova I; Slouka D; Kulda V
Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31234350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
